[{"NetIncomeLoss_1_Q3_USD":-2890662.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_2_Q3_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_2_Q3_USD":-149500000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":2545170.0,"CommitmentsAndContingencies_0_Q3_USD":null,"GeneralAndAdministrativeExpense_1_Q3_USD":2974634.0,"GeneralAndAdministrativeExpense_2_Q3_USD":3194739.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"ProceedsFromRelatedPartyDebt_2_Q3_USD":250000.0,"GainLossOnInvestments_1_Q3_USD":83972.0,"GainLossOnInvestments_2_Q3_USD":70559.0,"Liabilities_0_Q3_USD":7929462.0,"Cash_0_Q3_USD":609410.0,"IncreaseDecreaseInAccountsPayable_2_Q3_USD":151792.0,"PaymentsOfStockIssuanceCosts_2_Q3_USD":3543021.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2_Q3_USD":0.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q3_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_2_Q3_USD":150946979.0,"ProceedsFromIssuanceOfPrivatePlacement_2_Q3_USD":4990000.0,"AssetsHeldInTrustNoncurrent_0_Q3_USD":149570559.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":83972.0,"OtherNonoperatingIncomeExpense_2_Q3_USD":70559.0,"AssetsCurrent_0_Q3_USD":949202.0,"IncreaseDecreaseInPrepaidExpensesOther_2_Q3_USD":339792.0,"TemporaryEquitySharesOutstanding_0_Q3_shares":13725029.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q3_USD":137590290.0,"NetIncomeLoss_2_Q3_USD":-3124180.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"AdditionalPaidInCapital_0_Q3_USD":8123646.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":609410.0,"AccountsPayableCurrent_0_Q3_USD":151792.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q3_USD":609410.0,"LiabilitiesCurrent_0_Q3_USD":2696962.0,"NetCashProvidedByUsedInOperatingActivities_2_Q3_USD":-837569.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-3124180.0,"TemporaryEquityRedemptionPricePerShare_0_Q3_USD":10.0,"IncreaseDecreaseInAccruedLiabilities_2_Q3_USD":2545170.0,"StockholdersEquity_0_Q3_USD":5000009.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":150519761.0,"PreferredStockValue_0_Q3_USD":0.0,"ProceedsFromIssuanceInitialPublicOffering_2_Q3_USD":149500000.0,"OperatingIncomeLoss_1_Q3_USD":-2974634.0,"OperatingIncomeLoss_2_Q3_USD":-3194739.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q3_USD":0.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"Assets_0_Q3_USD":150519761.0,"RepaymentsOfRelatedPartyDebt_2_Q3_USD":250000.0,"PreferredStockSharesAuthorized_0_Q3_shares":1000000.0,"PrepaidExpenseCurrent_0_Q3_USD":339792.0,"Ticker":"CERE","CIK":"1805387","name":"CEREVEL THERAPEUTICS HOLDINGS, INC.","OfficialName":"Cerevel Therapeutics Holdings Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"4823550476.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20201116"}]